15Nov

A huge congratulations to BioLife customer TissueGene / Kolon Life Science on their first patient use of CryoStor - powered Invossa, a novel cell-mediated therapy for degenerative arthritis. Invossa is the world's first gene therapy for treating osteoarthritis of the knee, in which the cartilage that cushions the joints wears away, causing the bones to rub together and induce pain.

A single injection of the drug delivers therapeutic relief for up to two years, according to the firm. It was developed by Kolon Group's US-based bioparma subsidiary TissueGene, which went public on the Kosdaq recently. To read more, visit this article.

BioLife Solutions Inc. published this content on 15 November 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 15 November 2017 21:44:01 UTC.

Original documenthttps://www.biolifesolutions.com/uncategorized/kolon-life-science-launches-osteoarthritis-drug-invossa-korea/

Public permalinkhttp://www.publicnow.com/view/E9DE9ACF6ABE12BB23DCAACFDFFA21D3C8BBDBBA